JP2018504445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504445A5 JP2018504445A5 JP2017541786A JP2017541786A JP2018504445A5 JP 2018504445 A5 JP2018504445 A5 JP 2018504445A5 JP 2017541786 A JP2017541786 A JP 2017541786A JP 2017541786 A JP2017541786 A JP 2017541786A JP 2018504445 A5 JP2018504445 A5 JP 2018504445A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- trypsin inhibitor
- oral administration
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 7
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 7
- 239000002753 trypsin inhibitor Substances 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims 4
- 229960001319 parathyroid hormone Drugs 0.000 claims 4
- 239000000199 parathyroid hormone Substances 0.000 claims 4
- 244000068988 Glycine max Species 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010039627 Aprotinin Proteins 0.000 claims 1
- 244000045232 Canavalia ensiformis Species 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108010064983 Ovomucin Proteins 0.000 claims 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims 1
- 108010049264 Teriparatide Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000013022 formulation composition Substances 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
- 229960005460 teriparatide Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128296A JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113625P | 2015-02-09 | 2015-02-09 | |
| US201562113619P | 2015-02-09 | 2015-02-09 | |
| US201562113600P | 2015-02-09 | 2015-02-09 | |
| US201562113638P | 2015-02-09 | 2015-02-09 | |
| US201562113673P | 2015-02-09 | 2015-02-09 | |
| US201562113629P | 2015-02-09 | 2015-02-09 | |
| US201562113604P | 2015-02-09 | 2015-02-09 | |
| US62/113,673 | 2015-02-09 | ||
| US62/113,600 | 2015-02-09 | ||
| US62/113,619 | 2015-02-09 | ||
| US62/113,604 | 2015-02-09 | ||
| US62/113,625 | 2015-02-09 | ||
| US62/113,638 | 2015-02-09 | ||
| US62/113,629 | 2015-02-09 | ||
| PCT/IL2016/050151 WO2016128970A1 (en) | 2015-02-09 | 2016-02-09 | Treatment of hypoparathyroidism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128296A Division JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504445A JP2018504445A (ja) | 2018-02-15 |
| JP2018504445A5 true JP2018504445A5 (cg-RX-API-DMAC7.html) | 2019-03-07 |
| JP6925970B2 JP6925970B2 (ja) | 2021-08-25 |
Family
ID=56614456
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
| JP2017541786A Active JP6925970B2 (ja) | 2015-02-09 | 2016-02-09 | 副甲状腺機能低下症の治療 |
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Active JP7775239B2 (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Active JP7775239B2 (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20180028622A1 (cg-RX-API-DMAC7.html) |
| EP (5) | EP3256153A4 (cg-RX-API-DMAC7.html) |
| JP (6) | JP6925969B2 (cg-RX-API-DMAC7.html) |
| CN (5) | CN107427481A (cg-RX-API-DMAC7.html) |
| CA (3) | CA3011654A1 (cg-RX-API-DMAC7.html) |
| HK (5) | HK1247843A1 (cg-RX-API-DMAC7.html) |
| IL (7) | IL303216A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2017010220A (cg-RX-API-DMAC7.html) |
| WO (5) | WO2016128970A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2651398T (pt) | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| MY161450A (en) | 2011-04-12 | 2017-04-14 | Novo Nordisk As | Double-acylated glp-1 derivatives |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| PL2991671T3 (pl) | 2013-05-02 | 2019-01-31 | Novo Nordisk As | Doustne dawkowanie związków glp-1 |
| WO2016128970A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
| EP3500291A4 (en) * | 2016-08-17 | 2020-03-11 | Entera Bio Ltd. | FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES |
| JP6898518B2 (ja) * | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| JP7610410B2 (ja) * | 2019-03-08 | 2025-01-08 | アニヤ バイオファーム インク． | 副甲状腺ホルモンアナログの経口製剤および治療 |
| EP4025240B1 (en) * | 2019-09-03 | 2024-10-30 | Amgen Inc. | Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof |
| CN114306249A (zh) * | 2020-09-28 | 2022-04-12 | 深圳翰宇药业股份有限公司 | 一种特立帕肽冻干药物组合物及其制备方法 |
| US12251208B2 (en) * | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| CN114288388B (zh) * | 2022-01-25 | 2023-11-03 | 华中科技大学同济医学院附属协和医院 | 网膜素在制备炎症性肠病治疗药物中的应用 |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| KR20240145523A (ko) * | 2022-02-24 | 2024-10-07 | 엔테라 바이오 리미티드 | 글루카곤 유사 펩타이드-2의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 |
| CN119072329A (zh) * | 2022-02-24 | 2024-12-03 | 安提拉生物有限公司 | 包含酸中和聚合物用于口服甲状旁腺激素的制剂 |
| CN119031930A (zh) * | 2022-02-24 | 2024-11-26 | 安提拉生物有限公司 | 包含酸中和聚合物用于口服胰高血糖素样肽-1及其类似物的制剂 |
| EP4482507A1 (en) * | 2022-02-24 | 2025-01-01 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of active agents |
| WO2023161938A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide |
| WO2023161935A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone |
| WO2025046590A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations for oral administration of active agents |
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
| WO2025146144A1 (zh) * | 2024-01-05 | 2025-07-10 | 成都国为生物医药有限公司 | 一种地非法林的口服药物组合物 |
| WO2025240494A1 (en) | 2024-05-13 | 2025-11-20 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360793A (en) * | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
| CN1162917A (zh) * | 1994-10-07 | 1997-10-22 | 伯温德药品服务公司 | 肠内涂层组合物，用其涂覆的方法和涂覆制品 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| CA2220301C (en) * | 1995-06-02 | 2006-02-21 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
| JP3880093B2 (ja) | 1995-08-08 | 2007-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 錠剤 |
| JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| EP0943336A1 (en) | 1996-09-04 | 1999-09-22 | Dott Research Laboratory | Peptide-containing pharmaceutical compositions for oral administration |
| HUP0003349A3 (en) | 1997-05-14 | 2001-12-28 | Aventis Pharmaceuticals Inc Co | Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| WO2000048589A1 (en) * | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| WO2000050386A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| ES2235854T3 (es) | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| JP2004501057A (ja) | 1999-11-05 | 2004-01-15 | エミスフェアー・テクノロジーズ・インク | フェニルアミンカルボン酸化合物及び活性剤を送達するための組成物 |
| CN1437483A (zh) * | 1999-12-28 | 2003-08-20 | 味之素株式会社 | 口服给药用糖尿病药物制剂 |
| IL159714A0 (en) * | 2001-08-17 | 2004-06-20 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| WO2003045306A2 (en) | 2001-11-13 | 2003-06-05 | Emisphere Technologies, Inc. | Phenoxy amine compounds and compositions for delivering active agents |
| AU2002352974A1 (en) | 2001-11-29 | 2003-06-10 | Emisphere Technologies, Inc. | Formulations for oral administration of cromolyn sodium |
| CN1606434A (zh) | 2001-12-19 | 2005-04-13 | 株式会社三和化学研究所 | 控制释放成型品 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TWI307279B (en) * | 2002-08-01 | 2009-03-11 | Novartis Ag | Oral administration of calcitonin |
| EP1643978A1 (en) | 2003-07-04 | 2006-04-12 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| JP2005281231A (ja) | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| WO2006055928A2 (en) | 2004-11-19 | 2006-05-26 | Smithkline Beecham Corporation | Pharmaceutical product |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| EP1843755B1 (en) * | 2005-02-01 | 2015-04-01 | Emisphere Technologies, Inc. | Gastric retention and controlled release delivery system |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| JP5123471B2 (ja) | 2005-08-18 | 2013-01-23 | 帝人ファーマ株式会社 | 用量調整が容易な製剤 |
| JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| KR101432313B1 (ko) | 2005-11-17 | 2014-08-20 | 노파르티스 아게 | 약제학적 조성물 |
| US20070178155A1 (en) * | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| ES2538254T3 (es) | 2006-04-18 | 2015-06-18 | Emisphere Technologies, Inc. | Agentes de administración de dialquil éter |
| KR101428826B1 (ko) * | 2006-12-12 | 2014-08-08 | 가부시키가이샤 호리바 에스텍 | 유량 비율 제어 장치 |
| JP2010523555A (ja) | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | 「経口医薬組成物」 |
| EP2152244B1 (en) * | 2007-04-26 | 2015-12-02 | Technion Research & Development Foundation Ltd. | Oral administration of proteins and peptides |
| WO2009036084A2 (en) * | 2007-09-11 | 2009-03-19 | Orahealth Corporation | Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach |
| WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
| IT1393244B1 (it) | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| NZ591497A (en) * | 2008-08-18 | 2012-11-30 | Entera Bio Ltd | A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| EP2558106A1 (en) * | 2010-04-16 | 2013-02-20 | Novartis AG | Methods and compositions for improving implant osseointegration |
| PT2651398T (pt) * | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| US20130224300A1 (en) | 2011-08-26 | 2013-08-29 | Edward T. Maggio | Compositions and methods thereof for oral administration of drugs |
| US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| CN104487056A (zh) * | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| WO2016128970A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
| EP3500291A4 (en) | 2016-08-17 | 2020-03-11 | Entera Bio Ltd. | FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES |
| JP7419862B2 (ja) | 2020-02-14 | 2024-01-23 | 株式会社リコー | 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置 |
-
2016
- 2016-02-09 WO PCT/IL2016/050151 patent/WO2016128970A1/en not_active Ceased
- 2016-02-09 JP JP2017541780A patent/JP6925969B2/ja active Active
- 2016-02-09 CA CA3011654A patent/CA3011654A1/en active Pending
- 2016-02-09 EP EP16748833.7A patent/EP3256153A4/en active Pending
- 2016-02-09 US US15/549,425 patent/US20180028622A1/en active Pending
- 2016-02-09 CA CA2975710A patent/CA2975710C/en active Active
- 2016-02-09 EP EP16748835.2A patent/EP3256149A4/en active Pending
- 2016-02-09 IL IL303216A patent/IL303216A/en unknown
- 2016-02-09 US US15/549,394 patent/US20180036382A1/en active Pending
- 2016-02-09 CA CA2975676A patent/CA2975676A1/en active Pending
- 2016-02-09 JP JP2017541786A patent/JP6925970B2/ja active Active
- 2016-02-09 HK HK18107403.6A patent/HK1247843A1/zh unknown
- 2016-02-09 HK HK18107355.4A patent/HK1247835A1/zh unknown
- 2016-02-09 EP EP16748834.5A patent/EP3256114A4/en active Pending
- 2016-02-09 IL IL253802A patent/IL253802B/en unknown
- 2016-02-09 HK HK18107372.3A patent/HK1247838A1/zh unknown
- 2016-02-09 IL IL292218A patent/IL292218B2/en unknown
- 2016-02-09 US US15/549,418 patent/US20180036234A1/en active Pending
- 2016-02-09 WO PCT/IL2016/050152 patent/WO2016128971A1/en not_active Ceased
- 2016-02-09 CN CN201680016126.5A patent/CN107427481A/zh active Pending
- 2016-02-09 WO PCT/IL2016/050153 patent/WO2016128972A1/en not_active Ceased
- 2016-02-09 WO PCT/IL2016/050154 patent/WO2016128973A1/en not_active Ceased
- 2016-02-09 US US15/549,436 patent/US10583177B2/en active Active
- 2016-02-09 IL IL292417A patent/IL292417B2/en unknown
- 2016-02-09 MX MX2017010220A patent/MX2017010220A/es unknown
- 2016-02-09 EP EP16748831.1A patent/EP3256113B1/en active Active
- 2016-02-09 WO PCT/IL2016/050155 patent/WO2016128974A1/en not_active Ceased
- 2016-02-09 CN CN202111014609.0A patent/CN113694190B/zh active Active
- 2016-02-09 HK HK18107250.0A patent/HK1247822A1/zh unknown
- 2016-02-09 CN CN202111014634.9A patent/CN113730556A/zh active Pending
- 2016-02-09 CN CN202210601969.9A patent/CN114949185A/zh active Pending
- 2016-02-09 CN CN202111014352.9A patent/CN113713090B/zh active Active
- 2016-02-09 EP EP16748832.9A patent/EP3256152A4/en active Pending
- 2016-02-09 HK HK18107251.9A patent/HK1247823A1/zh unknown
- 2016-02-09 US US15/549,442 patent/US20180050096A1/en not_active Abandoned
- 2016-02-09 IL IL283258A patent/IL283258B2/en unknown
-
2017
- 2017-08-02 IL IL253803A patent/IL253803B/en active IP Right Grant
- 2017-08-02 IL IL253804A patent/IL253804B/en unknown
- 2017-08-08 MX MX2022014313A patent/MX2022014313A/es unknown
-
2019
- 2019-12-23 US US16/724,400 patent/US12076373B2/en active Active
-
2021
- 2021-08-04 JP JP2021128296A patent/JP2021176914A/ja active Pending
- 2021-08-04 JP JP2021128281A patent/JP7275207B2/ja active Active
-
2023
- 2023-02-06 JP JP2023015960A patent/JP7775239B2/ja active Active
- 2023-05-10 JP JP2023078011A patent/JP2023100920A/ja active Pending
-
2024
- 2024-02-05 US US18/432,185 patent/US20240181020A1/en active Pending
- 2024-08-09 US US18/798,864 patent/US20240398904A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504445A5 (cg-RX-API-DMAC7.html) | ||
| JP2018504444A5 (ja) | 医薬組成物 | |
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
| JP2015515459A5 (cg-RX-API-DMAC7.html) | ||
| WO2009095226A3 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
| JP2014129360A5 (cg-RX-API-DMAC7.html) | ||
| RU2015139742A (ru) | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| JP2014507482A5 (cg-RX-API-DMAC7.html) | ||
| MX381895B (es) | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. | |
| EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| WO2006010423A3 (en) | Azaindole inhibitors of mtp and apob | |
| CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
| JP2016505613A5 (cg-RX-API-DMAC7.html) | ||
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| JP2018527305A5 (cg-RX-API-DMAC7.html) | ||
| WO2012020301A3 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| WO2016118040A8 (ru) | Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| JP2016513650A5 (cg-RX-API-DMAC7.html) | ||
| RU2013157398A (ru) | Композиция | |
| WO2009084036A3 (en) | Composition for treatment of viral infections |